FDA Clears Radiology AI Enterprise Imaging Platform from CARPL.ai
Offering access to over 110 AI applications, the enterprise imaging platform enables radiologists to test, deploy and monitor the use of AI technologies.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the CARPL.ai enterprise imaging artificial intelligence (AI) platform, a development that may help streamline the adoption of AI into radiology workflows.
CARPL.ai noted the platform allows radiologists access to over 110 AI applications from over 50 vendors with a single user interface. The platform facilitates worklist triage, segmentation, clinical audits, and auto-populated reports, according to the company.
Noting the adaptable capability of the platform for on-site or cloud-based hosting, CARPL.ai emphasized the potential for rapid scaling with no incremental costs for piloting of AI applications.
Vijay Rao, M.D., FACR, a senior vice president of enterprise radiology and imaging ay Jefferson Health in Philadelphia, added that the FDA clearance of the CARPL.ai platform allows for PACS integration of FDA-cleared AI applications that don’t have separate FDA-cleared viewers.
“This FDA clearance opens the door for widespread adoption of AI solutions through a platform approach which simplifies the process of selection, implementation, and procurement of AI by health systems,” noted Vidur Mahajan, the chief executive officer at CARPL.ai.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
